Podcasts about Liver disease

Welcome to this week's Midlife Minute. Today, I'm focusing on all the questions I received about gallbladder health, including HRT-provoking symptoms, supplements that improve gallbladder health, and evidence-based food interventions. IN THIS EPISODE, YOU WILL LEARN: Why the risk of gallstones and gallbladder inflammation increases during the menopause transition How estrogen and progesterone HRT have different effects on gallbladder functioning The differences in risk between transdermal and oral HRT How the progesterone in HRT can cause gallbladder issues in some women What TUDCA is, and how it supports gallbladder health The value of TUDCA for women who have had their gallbladders removed How various nutrients and supplements support bile flow and gallbladder health What can contribute to gallstone formation Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Gallbladder Research: Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications. Seminars in Liver Disease. 2019;39(4):397–404. doi:10.1055/s-0039-1696799  Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Global Advances in Health and Medicine. 2014;3(3):58–69. doi:10.7453/gahmj.2014.017  Bai M, Yang L, Liao H, et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. Journal of Agricultural and Food Chemistry. 2024;72(41):22655–22668. doi:10.1021/acs.jafc.4c04630  Simon JA, Hudes ES. Relation of serum ascorbic acid to serum vitamin B12, serum ferritin, and kidney stones in US adults. *Archives of Internal Medicine.*1999;159(6):619–624. doi:10.1001/archinte.159.6.619  Walcher T, Haenle MM, Kron M, et al. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterology. 2009;9:74. doi:10.1186/1471-230X-9-74  Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. American Journal of Gastroenterology. 2004;99(7):1364–1370. doi:10.1111/j.1572-0241.2004.30281.x  Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannucci EL. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology. 2002;123(6):1823–1830. doi:10.1053/gast.2002.37085  Moerman CJ, Smeets FW, Kromhout D. Dietary risk factors for clinically diagnosed gallstones in middle-aged men — a 25-year follow-up study. Annals of Epidemiology. 1994;4(3):248–254. doi:10.1016/1047-2797(94)90099-x Association between dietary magnesium intake and gallstones: the mediating role of atherogenic index of plasma. Lipids in Health and Disease. 2024;23(1):82. doi:10.1186/s12944-024-02074-4  Pitt HA, Doty JE, Murphy MM, Schwarz MB. Progesterone alters biliary flow dynamics. Annals of Surgery. 1999;229(2):205–209. doi:10.1097/00000658-199902000-00008

In this episode, Drs. Jason Silverman and Amber Hildreth talk to Dr. Valeria Cohran about the advances in intestinal rehabilitation care for infants and children with short bowel syndrome including changes nutrition management, line care and use of GLP-2 analogues that have led to decreases in intestinal failure associated liver disease and transplantation. Learning objectivesTo understand the composition and impact of multidisciplinary intestinal rehabilitation teams.To review the historical presentation of intestinal failure-associated liver disease (IFALD) and changes in practice that have reduced its prevalence and severity.To review GLP-2 analogues and their impact on outcomes and quality of life for children with short bowel syndrome. LinksPapers mentioned:PIFCON data paper on IFALDCholestasis and infection in long-term PNManagement of CVL in SBS Position PaperIntestinal Rehabilitation Teams Practice GuidelinePrevious episodes mentioned:Sue Protheroe - Enteral Nutrition in Intestinal FailureDanielle Wendel - Central Line Management in Intestinal Failure (Special JPGN Episode)Ruben Quiros-Tejeira - Multivisceral TransplantationPaul Wales - Surgical Management in Short Bowel SyndromeValeria Cohran & Conrad Cole - Racism in MedicineSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Two adult siblings with unexplained liver disease, renal complications and intermittent haematological abnormalities but with one feature that seemed to argue against a metabolic diagnosis. In this Metabolic Mystery, Dr Greg Lynch explores how an attenuated presentation delayed recognition of the underlying disorder for years. Read the paper: https://doi.org/10.1002/jmd2.70079

Do you know how metabolic dysfunction and obesity impact liver health in your patients, and which therapies are in the pipeline for treating obesity-related liver disease? Credit available for this activity expires: 5/11/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/rapid-fire-your-questions-obesity-and-liver-disease-answered-2026a1000efi?ecd=bdc_podcast_libsyn_mscpedu

According to Hepatitis Australia, around 220,000 people in Australia are living with chronic Hepatitis B, with 4–5% of cases linked to people born in the Philippines. - Ayon sa Hepatitis Australia, tinatayang nasa 220,000 ang may chronic Hepatitis B sa bansa, 4 hanggang 5 porsyento sa kabuuang bilang ay mula sa Pilipinas.

As I have said many times before, some podcast ideas come from REAL clinic encounters. In this episode, Dr Hanna V, our dedicated PGY1 on our call team, and I will answer TWO real questions which arose just today on morning rounds, on our service: 1. Does NORMOTENSIVE HELLP still need Mag Sulfate? And 2. Does an indwelling foley s/p iatrogenic bladder injury at CS require prophylactic antibiotic coverage for urinary infection? Yep: It's a BOGO sale on today's podcast- Buy ONE GET ONE! Listen in for details.1. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.Obstetrics and Gynecology. 2020. Committee on Practice Bulletins—ObstetricsGuideline2. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T.SR. Corticosteroids for HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelets) Syndrome in Pregnancy.The Cochrane Database of Systematic Reviews. 2010. 3. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA.Liver Disease in Pregnancy. Lancet. 2010. Review4. Rimaitis K, Grauslyte L, Zavackiene A, et al.Observational. Diagnosis of HELLP Syndrome: A 10-Year Survey in a Perinatology Centre. International Journal of Environmental Research and Public Health. 20195. Reau N, Munoz SJ, Schiano T.Guideline Liver Disease During Pregnancy.The American Journal of Gastroenterology. 2022. 6. ACG Clinical Guideline: Liver Disease and Pregnancy.The American Journal of Gastroenterology. 2016. Tran TT, Ahn J, Reau NS.7. ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstetrics and Gynecology. 2018. Committee on Practice Bulletins—Gynecology Guideline8. Niels Johnsen, Hunter Wessells, Krystal Archer-Arroyo, et al. Best Practices Guidelines Management of Gentiunrinary Injuries.American College of Surgeons (2025). 20259. Fletke KJ, Jeong DH, Herrera AV . Urinary Catheter Management. American Family Physician. 2024..

Liver disease is often overlooked in primary care, yet it is one of the fastest-growing causes of morbidity and mortality in the UK. Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), now affects around one-third of the UK population, with prevalence rising and all-cause mortality worsening over time. In this second episode of a series on hepatology and hepatitis, Dr James Waldron is joined by Dr Rik Fijten (GP Partner, Hepatitis C GP Champion for Bexley and GP Clinical Fellow in Gastroenterology) to explore why MASLD matters to GPs, why it is so common and why primary care is central to identifying disease early and preventing progression. They discuss why clinicians need to raise this often “silent” disease proactively and how it should be considered alongside diabetes, hypertension and weight management. The conversation covers how to approach abnormal liver function tests, how to assess fibrosis risk using simple non-invasive tools and how MASLD fits into the wider cardio–renal–metabolic model of long-term condition care. The episode also looks ahead to emerging treatments and what the future may hold for patients.Access episode show notes containing key references and take-home points at:https://gpnotebook.com/en-GB/podcasts/infectious-disease/ep-205-metabolic-dysfunction-associated-steatotic-liver-disease-and-hepatitis.DisclaimerThis content is for medical education purposes only and does not constitute clinical advice. While specific drugs and dosages may be discussed, clinicians should always refer to local protocols and official prescribing information before administering medication.Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more.

In this episode of Bowel Sounds, hosts Drs. Amber Hildreth and Jennifer Lee talk to Dr. Elizabeth Rand, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at Children's Hospital of Philadelphia (CHOP), Medical Director of CHOP's Liver Transplant Program, Director of the Gastroenterology Fellowship Program and Director of the Advanced Transplant Hepatology Program. We talk everything about Fontan Associated Liver Disease (FALD), from diagnosis to management and future research opportunities in the field. Learning objectivesDescribe the pathophysiology of FALDUnderstand the management challenges in patients with FALDExplore the unanswered questions about FALD to help guide future research priorities Links:Single-cell multiomics guided mechanistic understanding of Fontan-associated liver diseaseSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Send us Fan MailMorning Prayer (Thank You LORD; Create In Us A Clean Heart; Liver Disease; Unborn Children)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Some GEN editors were in sunny San Diego covering the hottest research, trends, and products from the American Association for Cancer Research meeting. We kick things off with news from America's Finest City, particularly around the growing role of AI in oncology. Then we dive into two new research studies. In the first, scientists used CRISPR to identify genes in primary CD4+ T cells that promote or restrict HIV infection. The second study described engineered implantable liver constructs that could eventually serve as a stopgap for patients waiting for donor transplants. Finally, the acquisitions keep coming as Eli Lilly scoops up CAR T cell therapy developer Kelonia for $7B. Also, Revolution Medicines has shared some impressive data from a Phase III trial of its pancreatic cancer drug. Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: AACR 2026: A Video Update from San Diego By Julianna LeMieux, PhD, and Damian Doherty, GEN, April 21, 2026AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven EraBy Fay Lin, PhD, and Jonathan Grinstein, PhD, GEN, April 22, 2026Using AI in Healthcare Ethically by Considering HumanityBy Corinna Singleman, PhD, IPM, November 18, 202510x Genomics Unveils Atera Spatial Platform at AACR Meeting By Julianna LeMieux, PhD, GEN, April 19, 2026CRISPR Screens Map Human T‑Cell Genes That Promote or Block HIV Infection GEN, April 20, 2026Synthetic Biology and Tissue Engineering Grow Liver Tissue In‑Body GEN, April 20, 2026 StockWatch: Revolution's Phase III Pancreatic Cancer Data Dazzles Investors, Analysts By Alex Philippidis, GEN Edge, April 19, 2026 Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline By Alex Philippidis, GEN Edge, April 20, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

Can liver disease be prevented? Could lifestyle play a major role in reducing the risk and in the treatment if liver disease? What are the major causes of liver diseases? Dr. Ajaz is a highly trained clinician with a deep passion for Lifestyle Medicine. She holds certifications from the British Society of Lifestyle Medicine and the International Board of Lifestyle Medicine. I has the pleasure of speaking to her in her home in London where we talked about all things liver health, disease prevention and treatments.  In this deep dive, we cover:  The prevalence of liver disease What are the major factors that cause liver disease The signs and symptoms of the condition The role of lifestyle medicine in prevention, treatment and management  Dr. Ajaz earned her MPhil in Biochemistry and Molecular Biology, followed by a PhD in Diabetes, Endocrinology, and Metabolism from King's College London in 2016. With over 17 years of experience as both a medical doctor and a researcher in the translational field, she has dedicated her career to investigating non-invasive biomarkers and preventative strategies for early detection of chronic metabolic diseases. https://www.kch.nhs.uk/about/get-involved/groups-and-events/livfit/ https://www.provigilant.co.uk/wellness https://hssh.health/consultants/dr-saima-ajaz/

In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Saul Karpen, MD, PhD, and Robert Gish, MD, for a practical, clinician-focused discussion on the evolving role of genetic testing in cholestatic liver disease.As genetic panels become more widely used in hepatology, many clinicians are left wondering when to order these tests—and how to interpret the results when they come back. From unexplained cholestasis and AMA-negative PBC to intrahepatic cholestasis of pregnancy and atypical liver enzyme patterns, the conversation explores where genetic testing can add real clinical value.Karpen and Gish break down the basics of modern genetic panels, including how they've evolved over time, what clinicians should look for in results, and how to approach common challenges like variants of uncertain significance (VUS). The discussion also highlights key genes, such as ABCB4 and ABCB11, and explains how genetic findings can influence diagnosis, risk assessment, and treatment decisions.Read more: https://www.hcplive.com/view/liver-lineup-navigating-genetic-testing-in-cholestatic-liver-disease

Guests: Bubu Banini, MD, PhD Assistant Professor of Medicine (Digestive Diseases) Translational Research Director of the Metabolic Health and Weight Loss Program, Digestive Diseases; Vice Chief for Clinical Research, Digestive Diseases

Dr. Adam Striker welcomes Dr. Shamsuddin Akhtar, member of the ACE editorial board, for a discussion of the use of various narcotics in patients with liver disease. Listen in as they discuss how the liver metabolizes opioids in patients with cirrhosis, dosing considerations, and more. Recorded March 2026.

This month, Health Is the Key does double duty as we spotlight National Stress Awareness Month and IBS Awareness Month. If you're wondering what stress has to do with irritable bowel syndrome and other digestive disorders, you'll be glad you tuned in. We are lucky to be joined by Dr. Preeti Mehta, a gastroenterologist and founder of the private practice Digestive Disease Care. Dr. Mehta explains the effect the brain has on the digestive system and vice-versa. She also shares practical lifestyle habits that can support long-term gut health.    The Takeaway  We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider.  Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts.  Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine.  Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices.  Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents.   Guest Bio  Preeti Mehta, MD, is a board-certified gastroenterologist and hepatologist with over 25 years of experience in digestive health care. She serves as Vice President of Digestive Disease Care, a multi-physician gastroenterology practice, and oversees two large Ambulatory Surgical Centers serving patients across Long Island and Queens.  Dr. Mehta earned her Doctor of Medicine degree from the Icahn School of Medicine at Mount Sinai and completed her internship and residency in Internal Medicine at North Shore University Hospital in Manhasset, New York. She went on to complete a Research Fellowship in Hepatology at NewYork-Presbyterian Hospital, in affiliation with Weill Medical College of Cornell University and Rockefeller University. She also completed a Clinical Fellowship in Gastroenterology and Hepatology and an Advanced Endoscopy Fellowship in Endoscopic Ultrasound at the State University of New York. She is a member of the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy and the American Association for the Study of Liver Diseases. 

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Dr. Galati starts the program with a story about a conversation he had with this finance guy after buying a new car this past week. He has Amy McGorry join to share her story of liver disease. She tells us about the journey of having autoimmune hepatitis and primary biliary cholangitis (PBC). Dr. Galati also spends a few minutes on the misunderstanding the role of alcohol has on liver transplant. 

Do you know how to optimally identify, risk stratify, and treat your patients with obesity and MASLD or MASH? Credit available for this activity expires: 03/17/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/metabolic-crossroads-navigating-obesity-liver-disease-axis-2026a10007kf?ecd=bdc_podcast_libsyn_mscpedu

Host: Darryl S. Chutka, M.D.  Guest: Kathryn del Valle, M.D.  Chronic liver disease can result in a variety of complications which can involve multiple organs. One of these complications can occur in the pulmonary vascular system. Two of the most clinically significant include hepatopulmonary syndrome and Portopulmonary hypertension. Patients with these syndromes may present to their primary care provider and if the medical condition is unrecognized, it can affect morbidity and ultimately the prognosis of the patient. What are the early symptoms and physical findings of hepatopulmonary syndrome and Portopulmonary hypertension? How are they diagnosed, and should we be screening patients with chronic liver disease for these pulmonary vascular disorders? My guest for this podcast is Dr. Kathryn del Valle, from the Division of Pulmonary and Critical Care at the Mayo Clinic and we'll be discussing “Pulmonary Vascular Complications of Liver Disease”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Download the transcript here

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Listen to the podcast here

In this episode of Bowel Sounds, hosts Drs. Amber Hildreth and Jason Silverman talk to Dr. Saul Karpen, the inaugural chief scientific officer for the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, Richmond, Va., where he is a professor of internal medicine and adjunct professor in pediatric medicine at the VCU School of Medicine. We talk about new genetic discoveries in biliary atresia and the future goals of research on this important pediatric liver topic.Learning objectivesDescribe the pathophysiology of biliary atresia Understand the importance of early screening and new tools to assist in early detection Examine the newly discovered genetic etiology to biliary atresiaLinks:Guidance for the Primary Care Provider in Identifying Infants with Biliary Atresia by 2-4 Weeks of Life: Clinical ReportBilitool.orgLiver-Restricted Deletion of the Biliary Atresia Candidate Gene PKD1L1 Causes Bile Duct Dysmorphogenesis and CiliopathyStravitz-Sanyal Institute for Liver Disease and Metabolic HealthAASLDPrevious Episodes Mentioned:Bill Balistreri- Neonatal CholestasisJorge Bezerra- Advances in Biliary AtresiaDisclosures:Dr. Karpen has a non-reimbursed consulting relationship with Ipsen as BOLD PIDr. Hildreth serves as a consultant and speaker for IpsenSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Amir Hefni, CEO of Resolution Therapeutics. Resolution specialises in developing therapies for inflammatory and fibrotic diseases and is currently progressing a treatment for end-stage liver disease through clinical trial. Bruno spoke to Amir about how Resolution's therapy is addressing a critical unmet need and how long it could be before we see it available to patients.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper "Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" published in paper copy in Gut in March 2026. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://bit.ly/4rRJeUI).

Most of us drink caffeine and it is in many foods too such as chocolate.What are its impact on health? In this episode I look at the pros and cons of this ubiquitous every day legal drug.Links:Genetics of caffeine metabolism: https://www.sleepmattersperth.com.au/how-genetics-influence-caffeines-impact-on-sleep/Cognitive and physical performance: https://pmc.ncbi.nlm.nih.gov/articles/PMC4462044/Caffeine and Parkinson's Disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC7773776/Coffee and dementia risk: https://www.nature.com/articles/d41586-026-00409-yCoffee and Liver Disease: https://www.news-medical.net/news/20250921/Coffee-protects-the-liver-by-blocking-inflammation-and-scarring-review-finds.aspxCaffeine as pain relief: https://www.bbc.co.uk/news/articles/cgr44j201rzoSave your life in slow motion and those of others by subscribing now and sharing. Thank you for listening and for your support. It means a lot to me. Hosted on Acast. See acast.com/privacy for more information.

Send a textEvening Prayer (Salvation; Lung Disease; Liver Disease; Pain; Unborn Children)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

This episode dives into the often-overlooked intersection of hepatology and women's health. Tatyana Kushner and Andrea Goldstein share their professional journeys, from the high-intensity liver transplant units of UCLA to pioneering women's liver health programs and their personal connections to the field. The conversation focuses on the complexities of Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Biliary Cholingitis (PBC), highlighting the racial disparities in diagnosis and the critical need for genetic testing. Our guests discuss the challenges of clinical trials in pregnant populations and offer a roadmap for better preconception counseling, interdisciplinary care, and the power of patient advocacy.  Adding a deeply personal perspective, the host also shares her own experience with ICP, underscoring why early recognition and coordinated care are essential for protecting both maternal and fetal health. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Are the everyday products in your home silently increasing your toxic burden?In this hot health topic episode of Accelerated Health with Sara Banta, I uncover a shocking connection that could be affecting millions: Forever Chemicals and a Triple Risk of Liver Disease. I break down the latest research on PFAS (per- and polyfluoroalkyl substances)—commonly known as “forever chemicals”—and their alarming association with fatty liver disease, liver inflammation, and long-term liver dysfunction.These chemicals are found in nonstick cookware, food packaging, water-resistant fabrics, contaminated water, and even personal care products. Because they don't break down easily, they accumulate in the body over time—placing significant stress on your liver and metabolic health.If you're dealing with elevated liver enzymes, fatty liver, insulin resistance, unexplained weight gain, or chronic inflammation, this is an episode you don't want to miss.Your liver is your body's primary detox organ—and protecting it starts with awareness.Listen now as I uncover what you need to know to lower your toxic exposure, support your liver, and take control of your health.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powder • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • BodyBio PC (Phosphatidylcholine) https://www.acceleratedhealthproducts.com/products/bodybio-pc-phosphatidylcholine • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz • Accelerated Liver Flush Detox Cleanse https://www.acceleratedhealthproducts.com/products/liver-detox-cleanse Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode we discuss alcohol-related liver disease (ARLD), what it is, its treatment, and hear Lesley's experience as a survivor of ARLD and transplant. Lesley was a patient of Dr Ashwin Dhanda, a liver specialist, and both provide their insights into the condition and how society should do more to raise awareness of and prevent alcohol-related harm and ARLD.Ashwin Dhanda is Professor of Liver Medicine at the University of Plymouth and a liver specialist at University Hospitals Plymouth NHS Trust. He leads a programme of research around stigma in alcohol-related liver disease including identifying causes of stigma and how it affects people and designing interventions to tackle it.Lesley was diagnosed with ARLD in December 2019, which led to a liver transplant in December 2019. She is part of a liver support group supporting other patients and working as a patient representative with Ashwin on a research project around stigma in alcohol related liver disease and helping the research team design interventions to tackle it from a patient/peer perspective.Support the showIf you are interested in one-to-one support for your drinking with Dr James Morris, contact him at DrJamesMorris.com Sign up to receive new episodes to your inbox here. For more episodes visit https://alcoholpodcast.buzzsprout.com/Follow us on Instagram

Your poop can reveal early warning signs of serious health issues long before symptoms appear. In this episode, Ben Azadi explains how stool color, texture, and consistency reflect what's happening in your gut, liver, and metabolism. Ben breaks down three major red flags to watch for: pale or clay-colored stool linked to poor bile flow and liver dysfunction, black or tar-like stool that may indicate internal bleeding, and mucus or blood in the stool as a sign of chronic gut inflammation or damage. You'll learn why colon cancer, liver disease, and gut disorders often develop silently, how bile supports fat digestion, detoxification, and hormone balance, and why “feeling fine” doesn't always mean your body is healthy. The episode also covers practical steps to reduce inflammation, support liver health, improve bile flow, and restore healthy digestion through nutrition, lifestyle changes, and proper elimination. This conversation is about awareness, not fear, empowering you to recognize patterns early and take action before small signals turn into serious health problems.

In this special edition episode of Liver Lineup, recorded as part of HCPLive's This Year in Medicine series, hosts Nancy Reau, MD, and Kimberly Brown, MD, break down the most consequential updates of the year across primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH), highlighting data that may reshape both near-term management and longer-term treatment strategies.Key episode timestamps:0:00:00 – Intro0:00:40 – Underuse of second‑line therapy in PBC0:03:40 – Long‑term data on PPAR agonists (elafibranor, seladelpar) in PBC0:09:35 – PSC: elafibranor (Elmwood trial) and CCL24 mAb (nabokitug)0:15:56 – Cholestasis symptoms: fatigue and pruritus and PPAR impact0:20:20 – Autoimmune hepatitis: limitations of current therapy; new agent 

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by guest Jessica Mellinger, MD, to discuss rising prevalence, new care models, and evolving concepts in alcohol-associated liver disease (ALD).Key episode timestamps:0:00:00 – Introduction0:00:30 – Prevalence of alcohol use & ALD under-recognition0:04:22 – Origin and design of the integrated ALD clinic0:06:50 – Expansion and outcomes of integrated care0:10:33 – Workforce and access challenges0:12:21 – Metabolic ALD (MetALD) concept0:15:18 – GLP‑1 agonists for metabolic disease & AUD0:19:09 – “Food noise,” food addiction, and ultra‑processed foods0:22:38 – Liver transplantation in ALD & Dallas criteria0:27:27 – Outcomes after relapse & closing

Liver disease isn't just about alcohol, and it's way more common than most people realize.   In this episode of The Gut Show, @socalgastrodoc helps break down what your liver actually does, why cases are rising, how it's diagnosed, what's reversible, and where things like GLP-1s, supplements, and even coffee fit in.   If you've ever been told to "just drink less" or felt overwhelmed by perfection, this one's for you!   About our guest:  Dr. Wendi LeBrett is a double board-certified gastroenterologist and internal medicine physician. She holds a Bachelor of Arts in Economics from Stanford University and graduated from the University of California San Diego School of Medicine. She completed her internal medicine residency and gastroenterology subspecialty fellowship at UCLA. Her research has been published in several leading gastroenterology journals including Gastroenterology, The American Journal of Gastroenterology, Clinical Gastroenterology & Hepatology, and The Lancet Gastroenterology. Dr. LeBrett is a leading voice in gastroenterology on social media. She presented the presidential plenary at United European Gastroenterology Week 2025 on medical misinformation on social media and was awarded a Healio Gastroenterology Disruptor award as Social Media Influencer of the Year 2023. She has over 300K followers on social media and creates educational content as @socalgastrodoc. She is a trusted voice on gastrointestinal health and has been featured in the Wall Street Journal, TIME, SELF, the Huffington Post, Business Insider and Well+Good. She is the founder of ModernGut, a gastroenterology education platform. TikTok Instagram   Thank you to our partners:   @imodifyhealth is the leader in evidence-based, medically-tailored meal delivery offering Monash Certified low FODMAP, Gluten free, and Mediterranean meals - expertly crafted to help you achieve better symptom control AND improve overall health.    The best part? They make it easy by doing all prep work for you. Simply choose the meals you want, stock your fridge or freezer when meals arrive at your door, then heat and enjoy when you're ready. Delicious meals. Less stress. Complete peace of mind.   Check out modifyhealth.com and save 35% off your first order plus free shipping across the US with code: THEGUTSHOW.   @fodzyme is the world's first enzyme supplement specialized to target FODMAPs.   When sprinkled on or mixed with high-FODMAP meals, FODZYME's novel patent-pending enzyme blend breaks down fructan, GOS and lactose before they can trigger bloating, gas and other digestive issues.    With FODZYME, enjoy garlic, onion, wheat, brussels sprouts, beans, dairy and more — worry free! Discover the power of FODZYME's digestive enzyme blend and eat the foods you love and miss.   Visit fodzyme.com and save 20% off your first order with code THEGUTSHOW. One use per customer.   @mbiotaelemental is the next generation of the elemental diet. Developed with leading gastroenterologists and food scientists, it's the first formula that's both clinically effective AND genuinely easy to drink.   If you're looking for an option to support SIBO or your gut, mBIOTA Elemental may be one to consider. Learn more at mbiota.com and save 20% on their two-week protocol with code GUTIVATE  

In this final episode, Vallier explores the next steps for liver regeneration research, including stimulating liver regeneration with small molecules and lifestyle factors. He describes AI as a tool that should not be used in the wrong way, before wrapping up the discussion with his predictions for the next 5 years and the introduction of induced pluripotent stem cell clinical trials. Timestamps:00:55 – Research beyond organoids 02:01 – Lifestyle factors 03:47 – Research funding 04:13 – AI in biotechnology 05:13 – Future of regenerative medicine 07:04 – Vision for stem cell therapies

Malnutrition in hospitalized patients is common, costly, and often missed—especially in those with complex disease states. In this episode, we take a clinically focused look at how dietitians can better identify malnutrition in liver disease and why early, accurate diagnosis matters for patient outcomes.Our guest is Dr. Janette Hasse, a nationally recognized expert in critical care and transplant nutrition, FNCE presenter, longtime Editor-in-Chief of Nutrition in Clinical Practice, award-winning clinician, and leader of a large transplant nutrition team. With more than four decades of experience, she breaks down the evidence and real-world considerations shaping malnutrition diagnosis today.We discuss:✔ Why patients with liver disease are uniquely vulnerable to malnutrition✔ Limitations of traditional assessment methods in complex populations✔ The emerging role of CT imaging for body composition analysis✔ How updated GLIM criteria and terminology changes are impacting practice✔ Confusion around using AAIM vs GLIM and how clinicians can navigate both✔ Practical documentation strategies for care and reimbursement✔ Actionable clinical pearls for bedside dietitiansWhether you work inpatient, outpatient, transplant, GI, or critical care, this episode offers insight into how dietitians can strengthen the diagnostic process and advocate for better nutrition care.Listen now and access additional resources at dnsdpg.org.

Welcome to Episode 52 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! NSAIDs National Institutes of Health. (2022). Nonsteroidal antiinflammatory drugs. LiverTox: Clinical and research information on drug-induced liver injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548614/ LFTs / Drug-Induced Liver Injury American Association for the Study of Liver Diseases. (2023). Practice guidance on drug, herbal, and dietary supplement–induced liver injury. Hepatology. Retrieved from https://journals.lww.com/hep/fulltext/2023/03000/aasldpracticeguidanceondrug,herbal,and.28.aspx Toxicology Screening StatPearls Publishing. (2023). Toxicology screening. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK499901/ Academy of Diagnostic & Laboratory Medicine. (2023). Testing for drugs of misuse to support the emergency department. Retrieved from https://myadlm.org/science-and-research/academy-guidance/testing-for-drugs-of-misuse-to-support-the-emergency-department CT Utilization / Imaging American College of Emergency Physicians. (2022). The renewed necessity of robust clinical judgment in CT scan utilization. ACEP Now. Retrieved from https://www.acepnow.com/article/the-renewed-necessity-of-robust-clinical-judgment-in-ct-scan-utilization/ Appropriate Testing / Overuse Context Melnick, E. R., et al. (2023). GRACE-2: Guidelines for reasonable and appropriate care in the emergency department. Academic Emergency Medicine. Retrieved from https://onlinelibrary.wiley.com/doi/10.1111/acem.14495 More from us: Our CME courses: EM Boot Camp: https://courses.ccme.org/course/embootcamp/about EM Boot Camp Pharmacology Workshop: https://bit.ly/2I44xld Bouncebacks! Medical & Legal: https://courses.ccme.org/education/bouncebacks-medical-and-legal Mastering Emergency Imaging: https://courses.ccme.org/education/mastering-emergency-imaging Advanced EM Boot Camp: https://courses.ccme.org/course/advancedbootcamp/about Advanced ECG Workshop: https://bit.ly/aembc-ecg Advanced Imaging Workshop: https://bit.ly/aembc-imaging EM & Acute Care: https://courses.ccme.org/course/ema/about National EM Board Review: https://courses.ccme.org/course/nembr/about High Risk Emergency Medicine: https://courses.ccme.org/course/hrem The Heart Course: https://courses.ccme.org/course/theheartcourse The Cadaver-Based Procedures & Suturing Courses: https://courses.ccme.org/course/cadaver EM:Prep LLSA Review: https://courses.ccme.org/course/em-prep/about EMCert Module Mastery: https://courses.ccme.org/course/emcertmodule USC Trauma Course: https://courses.ccme.org/course/usc-trauma ACOEP Scientific Assembly: https://courses.ccme.org/course/acoep Mastering Acute Care Charting - 2023 Updates: https://courses.ccme.org/course/macc Flourishing in Medicine: https://courses.ccme.org/course/flourishing-in-medicine The DEA Licensee SUD Training Course: https://courses.ccme.org/course/dea ACOFP On-Demand: https://courses.ccme.org/education/acofp25-clinical-selects The Airway and Lung Course: https://courses.ccme.org/education/airway Mastering Pediatric Emergencies: https://courses.ccme.org/course/pediatric-em Innovations in ED Management: https://courses.ccme.org/course/innovationsined American Osteopathic Association Courses: https://aoa.coursehost.net EM Cases Summit: https://courses.ccme.org/education/em-cases-summit-2024 IncrEMentuM Conference – On-Demand: https://courses.ccme.org/education/incrementum-2025 Our social media: TikTok: https://www.tiktok.com/@ccmecourses Instagram: https://www.instagram.com/ccmecourses Facebook: https://www.facebook.com/CenterForMedicalEducation LinkedIn: https://www.linkedin.com/in/rickbukata Our podcasts: The 2 View Podcast (Free): Subscribe on Apple Podcasts https://apple.co/3rhVNZw​ Subscribe on Google Podcasts: http://bit.ly/2MrAHcD​ Subscribe On Spotify: http://spoti.fi/3tDM4im Risk Management Monthly Podcast (Paid CME): https://www.ccme.org/riskmgmt ** The information in this video is not intended nor implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained in this video is for general information purposes only and does not replace a consultation with your own doctor/health professional. The information in this video is for informational purposes only and not for the purpose of providing legal advice. You should contact your attorney to obtain advice with respect to any particular issue or problem. Nothing here should be construed to form an attorney-client relationship. ** emergencymedicine #cme

Physician-scientist Randall Stafford studies the effects of alcohol use on population health – the true health impact, he emphasizes. Stafford explains how early research suggested that drinking is beneficial – or at least not bad – for people. That mindset produced decades of wishful thinking based on inconsistent science driven by social, emotional, and industry forces. The small cardiovascular benefits, he says, are far outweighed by the risks of cancer, liver disease, depression, and other ills. Although the harms of low-level consumption are small, there is no safe level of alcohol use, Stafford tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Randall StaffordConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Randall Stafford, a professor of medicine at Stanford University.(00:03:35) Challenges in Alcohol ResearchWhy cultural norms and study limitations complicate evidence.(00:03:56) Historical Perspectives on DrinkingHow early studies suggested benefits and why those conclusions shifted.(00:09:12) Risk, Dose, and Drinking PatternsThe increased risks with binge drinking and higher doses of alcohol.(00:12:15) Health Benefits vs. Lifestyle EnjoymentClarifying what alcohol does—and does not—provide medically.(00:13:37) Alcohol and Mental HealthThe bidirectional effects between alcohol use and mental health.(00:17:37) Broader Mental and Social EffectsAlcohol's connection to bipolar disorder, unemployment, and social harm.(00:20:12) How Alcohol Myths PersistWhy simplified conclusions endured despite contradictory data.(00:22:46) Changing Cultural AttitudesCultural trends toward reduced drinking and alcohol-free periods.(00:25:49) Alcohol and Liver DiseaseThe effects of alcohol beyond heavy use, including metabolic disease.(00:27:29) Strategies to Reduce HarmWay to reduce alcohol consumption and avoid binge drinking.(00:29:25) Future In a MinuteRapid-fire Q&A: avoiding alcohol, research needs, and studying liver disease.(00:31:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chris Burns was a successful cinematographer and director of photography for multiple Emmy-winning projects. Then he developed significant alcohol-associated liver disease which eventually led him to a liver transplant. He is now two years post transplant and is working on a documentary to raise awareness for both liver disease and liver transplantation. We discuss his journey and his advocacy work in today's episode of the Gut Doctor Podcast. This episode is brought to you by Mindray and Aegle Medical, manufacturer and distributor of the Hepatus-series platform, which is a NexGen vibration-controlled elastography technology used to stage and monitor liver disease.

Nutritionist Leyla Muedin discusses the renaming of fatty liver disease to metabolic dysfunction-associated steatotic liver disease (M-A-S-L-D) to reduce stigma and improve diagnosis. Dr. Mary Ella's efforts at the University of Chicago Medicine highlight how this change aids in better patient identification and treatment. Leyla emphasizes lifestyle changes like a low-carb diet to manage and reverse the disease. The episode also covers the prevalence of fake extra virgin olive oil (EVOO) on the market, ways to identify authentic olive oil, and the importance of choosing quality over mass-produced options.

Program notes:0:40 IVF clinics and private equity1:40 Provide over 54% of all IVF cycles in U.S.2:41 Perhaps a more positive result3:30 EKGs and liver cirrhosis4:30 New diagnosis of advanced liver disease5:30 Most physicians didn't follow up6:18 Management of acute back pain7:18 Did it improve pain or disability?8:18 Four- to eight-hour-long sessions to teach8:46 Lay health worker led intervention for older adults with cancer9:46 Reviewed with advanced practice practitioners10:46 Huge benefit from modest intervention11:46 Pick up the phone and ask12:20 Modest outlay13:09 End

Don't miss out — elevate your skills and save $100 on any online course with code START26! Join our library of live and on-demand veterinary dental courses here: https://internationalveterinarydentistryinstitute.org/veterinary-dental-online-webinars-courses-discount/?utm_source=podcast&utm_medium=podcastlink&utm_campaign=start26  —------------------------------------------------------------------- Host: Dr. Brett Beckman, DVM, FAVD, DAVDC, DAAPM In this episode of The Vet Dental Show, Dr. Victoria Lukasik, DVM, DACVAA, tackles the complexities of managing high-risk dental cases. Through detailed case studies, they discuss anesthetic protocols for patients with hepatic portal shunts and chronic heart failure. Learn how to navigate potential complications like hypoglycemia, hemorrhage, and ventricular tachycardia, while ensuring patient safety and optimizing recovery. What You'll Learn:  ✅ Understand anesthetic considerations for patients with hepatic portal shunts.  ✅ Discover strategies for managing hypoglycemia and electrolyte imbalances.  ✅ Simplify anesthetic protocols for patients with chronic heart failure.  ✅ Apply techniques for recognizing and treating ventricular tachycardia.  ✅ Master the use of short-acting and reversible drugs in high-risk patients.  ✅ Recognize and address delayed recovery in the post-anesthetic period. Key Takeaways:  ✅ Patients with hepatic portal shunts require short-acting, reversible drugs to minimize liver burden.  ✅ Intermittent hemorrhage in patients with hepatic dysfunction may lead to platelet consumption and anemia.  ✅ Bounding femoral pulses can indicate dehydration; adjust fluid therapy accordingly in cardiac patients.  ✅ Lidocaine has centrally depressing effects; anticipate mental dullness or sedation post-administration.  ✅ Early intervention with lidocaine is crucial for managing ventricular tachycardia and preventing further complications. Questions This Episode Answers: ❓ How should anesthetic protocols be adjusted for patients with hepatic portal shunts? ❓ Which anesthetic and analgesic drugs are safest for patients with true hepatic dysfunction? ❓ When should dextrose supplementation be considered in dental patients with liver disease? ❓ How do you manage intermittent hemorrhage, anemia, and low platelets during dental procedures? ❓ What causes delayed anesthetic recovery—and how do you systematically troubleshoot it? ❓ How should cardiac medications be handled on the morning of anesthesia for heart failure patients? ❓ What do bounding femoral pulses indicate, and how should fluid therapy be adjusted? ❓ Why can lidocaine cause deep sedation and delayed recovery after anesthesia? ❓ How do you recognize ventricular tachycardia intraoperatively—and when should you intervene? ❓ What recovery expectations should you have after treating ventricular tachycardia with lidocaine? —------------------------------------------------------------------- Explore Dr. Beckman's complete library of veterinary dentistry courses and CE resources! Save $100 on any online course with code START26! https://internationalveterinarydentistryinstitute.org/veterinary-dental-online-webinars-courses-discount/?utm_source=podcast&utm_medium=podcastlink&utm_campaign=start26  —------------------------------------------------------------------- Questions? Leave a comment below with your thoughts, experiences, or cases related to veterinary dentistry! —------------------------------------------------------------------- KEYWORDS: Veterinary Dentistry, IVDI, Brett Beckman, Dog Dental Care, Cat Dental Care, VetTech Tips, Animal Health, Veterinary Education, Veterinary Dental Practitioner Program, Vet Dental Show, Anesthesia, High-Risk Patients, Hepatic Portal Shunt, Chronic Heart Failure, Ventricular Tachycardia, Lidocaine, Hypoglycemia, Electrolyte Imbalance, Delayed Recovery

Dr. Venkat Katapatna breaks down the newly adopted MASLD nomenclature and its implications for diagnosing and managing metabolic dysfunction–associated steatotic liver disease. He highlights updated AASLD guidelines, the expanding role of advanced imaging, and how radiologists are central to early detection, treatment selection, and longitudinal disease monitoring. Current Update on Nomenclature, Diagnosis,and Management of Metabolic Dysfunction–associated Steatotic Liver Disease:Radiologists' Perspective. Osta et al. RadioGraphics 2025; 45(12):e240221.   

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wonder how much your liver really affects your overall health and weight? The liver plays a central role in metabolism, yet its importance is often underestimated.In this week's episode, we spoke with Dr. Rajvanshi, a board-certified gastroenterologist, hepatologist, and obesity medicine specialist at Valley Medical Center in Riten, Washington. Beyond his clinical practice, he's a health technology entrepreneur, developing AI tools to support obesity medicine for both clinicians and patients, and he is actively involved in the Obesity Medicine Association.Topics we covered include:The Liver: More Than a Detox OrganLiver Damage Can Be ReversedFatty Liver to Fibrosis: What You Need to KnowWhy Fatty Liver Screening Is EssentialSupplements vs. Real Nutrition for Liver HealthAlcohol's Impact on Your LiverModern Treatments: Resmetirom, Semaglutide, and Liver HealthMany people think of the liver simply as the body's detoxifier, but it's far more complex and vital. It supports metabolism, nutrient processing, and overall health. Understanding and maintaining liver health is key to long-term wellness, especially when it comes to weight management and metabolic health.Dr. Rajvanshi's approach highlights a modern principle in medicine: treat the root causes, not just the symptoms. By addressing liver care alongside metabolic health and obesity medicine, clinicians can help patients prevent serious complications, reduce the need for invasive treatments, and improve quality of life.For a deeper dive into how these insights translate into real-life health and weight outcomes, the full conversation is well worth a listen.Connect with Dr. Rajvanshi.:LinkedIn: Pankaj Rajvanshi, MD, Dipl. ABOMConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Mardi Dier, CFO of Madrigal Pharmaceuticals (MDGL), spotlights their latest quarter and the launch of their first product. Their drug treats liver disease (specifically MASH), and she says they are already on track for $1 billion in sales. Mardi also highlights their strong balance sheet, international expansion, and an extended patent. She stresses that there are millions of patients living with MASH, and there are few other therapies in the field. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

This week on Health Matters, Courtney sits down with Dr. Braden Kuo, Chief of the Division of Digestive & Liver Diseases at NewYork-Presbyterian and Columbia. Dr. Kuo covers common gut problems during the holiday season, a time of indulgent meals and treats. From bloat to heartburn to travel-related stomach issues, Dr. Kuo is a trove of information and practical tips for navigating holiday festivities with good choices for your gut.  ___ Dr. Braden Kuo is a leading neurogastroenterologist specializing in gastrointestinal motility and the relationship between the brain, nervous system and digestive system. He is the Chief of the Division of Digestive and Liver Diseases at NewYork-Presbyterian/ColumbiaUniversity Irving Medical Center and Columbia University Vagelos College of Physicians andSurgeons. Dr. Kuo received his medical degree from Jefferson Medical College and completed his residency at the University of Texas Southwestern Medical Center before arriving at Massachusetts General Hospital, where he served as director of the Center for Neurointestinal Health. He also completed formal training in clinical research, earning a Master of Science from the Harvard T.H. Chan School of Public Health, and subspecialty training in neurogastroenterology and motility at Mayo Clinic.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

In this weekly roundup, JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin discuss "MASLD—The Chronic Liver Disease That Affects Tens of Millions of US Adults but Flies Under the Radar" and more. Related Content: Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults MASLD—The Chronic Liver Disease That Affects Tens of Millions of US Adults but Flies Under the Radar ------------------------ jamamedicalnews.com

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠Alcoholic Liver Disease⁠⁠ from the Gastrointestinal section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Monica Tincopa, Assistant Professor of Medicine at the University of California San Diego, for a crucial conversation about Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its profound implications for cardiovascular care. Dr Tincopa guides listeners through the recent transformation from NAFLD to MASLD, explaining why this nomenclature change represents more than just terminology, instead reflecting a deeper understanding of metabolic health that directly impacts cardiology practice. The conversation explores practical screening strategies that cardiologists can implement immediately, including the use of FIB-4 risk stratification and recognizing incidental findings on cardiac imaging. Dr Tincopa shares insights on when to refer patients to hepatology specialists and how the shared risk factors between MASLD and cardiovascular disease create opportunities for comprehensive patient care. This episode equips cardiologists with essential knowledge to identify at-risk patients within their existing practice, understand the cardiovascular implications of liver disease, and optimize care coordination for patients with overlapping metabolic conditions. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Here is a real-world clinical case with a tricky differential: Our team recently readmitted a patient 6 days postpartum/post C-section (which was done for ICP and fetal macrosomia at close to 4500 grams, with A2GDM). She had elevated blood pressures, a frontal headache, some midepigastric pain/RUQ discomfort. Pretty clear picture right: sounds like preeclampsia (PreE) with severe features based on BP elevation and symptoms. So, we started her on mag-sulfate per protocol. Well, her transaminases were in the 400-600s, which was significantly higher than they were at delivery. They then peaked the next day at 900! OK, it still meets criteria for PreE with severe features. But could this also be postpartum Acute fatty Liver of Pregnancy (AFLP)? The clinical picture of these 2 conditions may overlap but there are distinct differences here. AFLP is potentially fatal, so we have to get that diagnosis correct. How can we distinguish AFLP from PreE with severe features or HELLP? Listen in for details.1. https://www.preeclampsia.org/the-news/health-information/acute-fatty-liver-of-pregnancy-can-be-confused-with-preeclampsia-and-hellp-syndrome2. Yemde A Jr, Kawathalkar A, Bhalerao A. Acute Fatty Liver of Pregnancy: A Diagnostic Challenge. Cureus. 2023 Mar 26;15(3):e36708. doi: 10.7759/cureus.36708. PMID: 37113350; PMCID: PMC10129069.3. Maalbi O, Elachhab N, Elkabbaj A, Arfaoui M, Hindi S, Lahbabi S, Oudghiri N, Tachinante R. Management of Acute Fatty Liver of Pregnancy: A Retrospective Study of 12 Cases Compared With Data in the Literature. Cureus. 2025 Jun 11;17(6):e85753. doi: 10.7759/cureus.85753. PMID: 40656400; PMCID: PMC12247011.4. Siwatch S, De A, Kaur B, et al. Safety and Efficacy of Plasmapheresis in Treatment of Acute Fatty Liver of Pregnancy-a Systematic Review and Meta-Analysis.Frontiers in Medicine. 2024;11:1433324. doi:10.3389/fmed.2024.1433324.5. Sarkar M, Brady CW, Fleckenstein J, et al.6. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.). 2021;73(1):318-365. doi:10.1002/hep.31559.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG